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Abstract 
One of the principal neurotransmitters of the central nervous system is GABA. In the adult brain, 
GABA is predominantly inhibitory, but there is growing evidence indicating that GABA can shift to 
excitatory action depending on environmental conditions. In the mammalian central circadian clock 
of the suprachiasmatic nucleus (SCN) GABAergic activity shifts from inhibition to excitation when 
animals are exposed to long day photoperiod. The polarity of the GABAergic response (inhibitory 
versus excitatory) depends on the GABA equilibrium potential determined by the intracellular Cl- 
concentration ([Cl-]i). Chloride homeostasis can be regulated by Cl- cotransporters like NKCC1 and 
KCC2 in the membrane, but the mechanisms for maintaining [Cl-]i are still under debate. This study 
investigates the role of KCC2 on GABA-induced Ca2+ transients in SCN neurons from mice exposed to 
different photoperiods.  We show for the first time that blocking KCC2 with the newly developed 
blocker ML077 can cause a shift in the polarity of the GABAergic response. This will increase the 
amount of excitatory responses in SCN neurons and thus cause a shift in excitatory/inhibitory ratio. 
These results indicate that KCC2 is an essential component in regulating [Cl-]i and the equilibrium 
potential of Cl- and thereby determining the sign of the GABAergic response. Moreover, our data 
suggest a role for the Cl- cotransporters in the switch from inhibition to excitation observed under 
long day photoperiod. 
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1. Introduction 
The balance between neuronal inhibition and excitation is critical for proper brain functioning 
(Buzsaki et al., 2007; Haider et al., 2006). Accordingly, an imbalance is implicated in several 
neurological disorders, like epilepsy and autism (Marín, 2012; Nelson and Valakh, 2015; Sgadò et al., 
2011). One of the important factors for keeping this balance is γ-Aminobutyric acid (GABA), known as 
the major inhibitory neurotransmitter in the central nervous system (Costa, 1998; Sivilotti and Nistri, 
1991).  In the developing brain, however, GABA can act as an excitatory neurotransmitter (Ben-Ari, 
2002), and even in the mature brain, the phenomenon of GABAergic depolarization has recently 
been recognized and characterized in multiple areas (Chung, 2012). One of these brain areas is the 
mammalian central circadian clock, located in the suprachiasmatic nucleus (SCN) of the anterior 
hypothalamus (Choi et al., 2008; De Jeu and Pennartz, 2002; Wagner et al., 1997). GABA is the 
prevalent neurotransmitter in the SCN and involved in synchronization within the neuronal network 
and in processing photic as well as non-photic entrainment (Albers et al., 2017). While exogenous 
applied GABA causes an inhibitory effect on the firing rate in many SCN neurons, it has a distinct 
excitatory effect on a subset of neurons in the SCN. The excitation is typically found in the neurons of 
the dorsal part of the SCN and is especially present during the night (Choi et al., 2008). Interestingly, 
exposure to long day photoperiod changes the GABAergic excitation/inhibition ratio (E/I ratio) in SCN 
neurons towards more excitation compared to short day photoperiod (Farajnia et al., 2014). This 
demonstrates that GABAergic excitation can have a physiological function in the SCN of the mature 
brain, and that its effect is plastic, i.e. under the control of environmental conditions.  
The major ion that passes through the GABAA receptor is chloride (Cl-) (Macdonald and Olsen, 1994). 
The concentration gradient of Cl- (the difference between internal and external concentrations) 
determines the equilibrium potential of chloride (ECl). Depending on the relationship between the ECl 
and the membrane potential (Vm), GABA acts either excitatory or inhibitory when binding to its 
receptor (Ben-Ari, 2002; Kaila, 1994). 
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It has generally been assumed that cation-chloride-cotransporters (CCCs) play a crucial role in 
maintaining the intracellular chloride concentration ([Cl-]i). In neurons, mainly two types of CCCs 
regulate [Cl-]i; the Na+-K+-2Cl- cotransporter 1 (NKCC1) and the K+-Cl- cotransporter 2 (KCC2), which 
carry Cl- in and out of the cell, respectively (Blaesse et al., 2009; Deeb et al., 2011; Gamba, 2005). 
Glykys et al. recently challenged this view by showing that immobile negative charges near the 
extracellular surface of the cell membrane and cytoplasmic impermeant anions may also play a 
prominent role in determining [Cl-]i (Glykys et al., 2014a).  
Investigating the  mechanism of [Cl-]i regulation requires specific blockers for CCCs and a recent study 
using an improved KCC2 antagonist suggests a primary role of KCC2 in [Cl-]i of SCN neurons (Klett and 
Allen, 2017). We used a recently developed and highly selective KCC2 antagonist; VU0255011; also 
known as ML077, which has over a hundredfold higher specificity for KCC2 over NKCC1 (Delpire et al., 
2009; Lindsley et al., 2010). With this pharmacological tool, we were able to investigate the role of 
KCC2 in the GABAergic response. Here, we show that blocking KCC2 with ML077 can cause a shift in 
the polarity of the GABAergic response by inducing excitatory responses in previously inhibitory 
responding neurons. These results indicate that KCC2 is an essential component  in regulating [Cl-]i 
and the ECl, thereby determining the sign of the GABAergic response. 
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2. Materials and methods 
2.1 Animals  
Male C57BL/6 mice (Envigo, Horst, the Netherlands; 8–10 wk. old; n = 35) were housed in a climate 
controlled environment (21˚C, 40-50% humidity) on an equinoctial photoperiod of 12h light-dark 
(12:12; LD12:12), a long photoperiod (LP; LD16:8), or a short photoperiod (SP; LD8:16). Food and 
water were available ad libitum. Before recordings, the mice were exposed to their respective 
photoperiod for a minimum of 30 days to ensure entrainment to the given light schedule. 
Experiments were performed within a 4-h interval centered around the middle of the light-phase of 
the photoperiod. All animal experiments were performed in accordance with the regulations of the 
Dutch law on animal welfare, and the institutional ethics committee for animal procedures of the 
Leiden University Medical Center (Leiden, The Netherlands) approved the protocol.  
2.2 Slice preparation 
After decapitation, brains were quickly removed and placed into modified ice-cold artificial 
cerebrospinal fluid (ACSF), containing (in mM): NaCl 116.4, KCl 5.4, NaH2PO4 1.0, MgSO4 0.8, CaCl2 1, 
MgCl2 4, NaHCO3 23.8, glucose 15.1, and 5 mg/L gentamycine (Sigma Aldrich, Munich, Germany) and 
saturated with 95% O2 – 5% CO2. Coronal hypothalamic slices containing the SCN (250 μm) were cut 
using a vibratome (VT 1000S, Leica Microsystems, Wetzlar, Germany) and sequentially maintained in 
regular, oxygenated ACSF (CaCl2 increased to 2 mM and without MgCl2). The slices were incubated in 
a water bath (37˚C) for 30 minutes and were then maintained at room temperature until the start of 
the recordings.  
2.3 Ca2+ imaging 
Neurons in brain slices were bulk-loaded with the ratiometric, membrane permeable Ca2+ indicator 
dye fura-2-acetoxymethyl ester (Fura-2-AM) as described previously (Michel et al., 2013). Briefly, the 
slices were submerged into a mix of ACSF containing 7 µM Fura-2-AM for 10 minutes at 37˚C. The 
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slices were then rinsed four times with fresh ACSF before being transferred to a recording chamber 
(RC-26G, Warner Instruments, Hamden, CT, USA) mounted on the fixed stage of an upright 
fluorescence microscope (Axioskop 2-FS Plus, Carl Zeiss Microimaging, Oberkochen, Germany) and 
constantly perfused with oxygenated ACSF (2.5 mL/min) at room temperature. The indicator dye was 
excited alternatively at wavelengths of 340 and 380 nm by means of a monochromator (Polychrome 
V, TILL Photonics; now FEI Munich GmbH, Munich, Germany). Emitted light (505 nm) was detected by 
a cooled CCD camera (Sensicam, TILL Photonics; now FEI Munich GmbH, Munich, Germany), and 
images were acquired at 2 second intervals (Fig 1). Using an eight-channel pressurized focal 
application system (ALA-VM8, ALA scientific instruments, NY, USA) GABA (200 μM, 15 s) was applied 
locally and neuronal responses were recorded as Ca2+ transients. After two GABA pulses, which were 
separated by 1 minute baseline recording, ACSF containing elevated levels of K+ (20 mM, 15 s) was 
applied to identify healthy, responding neurons. Cells with at least 10% increase in [Ca2+]i in response 
to high levels of K+ were considered as healthy cells. This protocol was repeated after 10 min 
incubation with either the drug ML077 (diluted in ACSF, 10 μM from 28 mM DMSO stock) or DMSO 
(diluted in ACSF, 4 ppm) via bath application (ML077: LP: n = 557 cells from eight animals; SP: n = 387 
cells from eight animals; 12:12: n = 499 cells from eight animals. DMSO: LP: n = 319 cells from four 
animals; SP: n = 149 cells from three animals; 12:12: n = 248 cells from four animals). Both 
experiments and analysis were accomplished using imaging software (TILLvision, TILL Photonics; now 
FEI Munich GmbH, Munich, Germany). Single-wavelength images were background subtracted, and 
ratio images (340/380) were generated. Region of interest-defined cells and mean ratio values were 
determined, from which the intracellular Ca2+ concentration was calculated.  
2.4 Chemicals 
GABA, DMSO and all salts were purchased from Sigma-Aldrich. The first badge of ML077 was 
generously provided by Dr. Craig Lindsley (Vanderbilt University, Nashville, TN, USA) and thereafter 
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purchased from AOBIOUS (Gloucester, MA, USA). Fura-2-AM was purchased from TEFlabs (Austin, TX, 
USA). 
2.5 Data analysis and statistics 
Neuronal Ca2+ responses were analyzed using IGOR Pro (WaveMetrics, Portland, OR, USA). The 
transient responses in Ca2+ concentration within the first seconds after the stimulation were 
evaluated, with responses smaller than ± 5% of baseline values defined as non-responding cells. 
GABA-evoked responses showing Ca2+ transients with a decrease in amplitude lower than 5% from 
baseline were considered inhibitory and responses with an increase higher than 5% from baseline 
were defined as excitatory. Cells that showed both excitatory and inhibitory responses after one 
GABA stimulation were defined as biphasic. Per animal, two to three SCN slices were analyzed and 
the Ca2+ responses to GABA application were measured in 50 – 80 cells. For each animal we 
calculated the distribution of the different types of responses and the E/I ratio. To calculate the E/I 
ratio, we divided the number of cells that responded excitatory by the number of cells that 
responded inhibitory, per animal. Subsequently, we took the average of all the E/I ratios of all 
animals per group. 
Statistical analysis was performed using SPSS (IBM, Armonk, NY, USA). We have used generalized 
estimating equations (GEE) to test if the average distribution of the GABA-induced responses 
(percentages of the 4 different types of responses) differs before and after treatment (ML077 or 
DMSO). We have used a multinomial regression model for the GEE and robust standard errors were 
calculated. We have used the number of cells per animal as a scale weight variable in the GEE to 
(extra) take into account the variability of the number of cells measured per SCN. Additional Wald 
tests shows whether the outcome of the GEE is significant. The effect of the treatment on the E/I 
ratio was tested with two-sided, paired t-tests, and the effect on baseline [Ca2+]i was tested with the 
Mann-Whitney test, because these data did not pass the Shapiro-Wilk normality tests. Differences 
with P ≤ 0.05 were considered significant. 
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3. Results/Discussion 
Using Ca2+ imaging, we tested the effect of the recently developed KCC2 blocker ML077 on 
GABAergic responses in SCN cells. Previous studies have shown that Ca2+ transients are a reliable 
estimate of the neuronal activity, with elevations and reductions in [Ca2+]i reflecting depolarization 
and hyperpolarization, respectively (Choi et al., 2008; Irwin and Allen, 2007; Irwin and Allen, 2009). 
GABAergic responses have been shown to be more excitatory during the night compared to the day 
(Choi et al., 2008; De Jeu and Pennartz, 2002), so we selected the mid-day for recordings to maximize 
the effect of ML077. Blocking KCC2 with ML077 caused an increase in excitatory responses after 
exogenous application of GABA (Fig 1 and Fig 2A; Wald chi2(1) = 23.61, p = 1 x 10-6, n = 8), leading to 
a change in E/I ratio from 0.95 to 3.41 (Fig 2B + 2C; t(7) = 3.45, p = 0.011, n = 8). To investigate which 
cells switched to the excitatory response type, we compared neurons before and after incubation 
with ML077. In 37% of all the cells, the type of the GABAergic response changed as a result of KCC2 
blockage. Of the cells that initially responded to GABA in an inhibitory manner, 26% (n=55) became 
excitatory after incubation with ML077. About half of the inhibitory cells stayed inhibitory (n = 107; 
51%) and the remaining inhibitory neurons became either biphasic (n = 14; 7%) or did not respond to 
GABA anymore (n = 35; 17%) Moreover, half of the neurons that initially did not respond to GABA (n 
= 48; 56%) and the majority of the biphasic responding neurons (n = 20; 69%) became excitatory as a 
result of ML077 application (Fig S1 + Fig 3A; Wald chi2(1) = 23.61, p = 1 x 10-6, n = 8). Since ML077 
was dissolved in DMSO, we’ve used DMSO as control experiments. The control slices, incubated in 
ACSF containing the solvent DMSO (4 ppm), did not show alteration in the GABAergic response types 
(Fig S2 + Fig 3B; Wald chi2(1) = 1.40, p = 0.24, n = 4) nor did it show a shift in the E/I ratio (0.68 to 
1.07, paired t-test; t(3) = 2.60, p = 0.08). Thus, the data demonstrate that the shift in E/I ratio is 
caused by inhibition of KCC2 by ML077. 
We next performed Ca2+ imaging experiments with slices from animals entrained to long- and short 
days to determine whether KCC2 may play a role in photoperiod-induced changes in E/I ratio 
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reported previously (Farajnia et al., 2014). ML077 increased the percentage of cells showing 
excitatory responses in short photoperiod from 24% to 43%, which is equivalent to the fraction found 
after adaptation to long photoperiod conditions (Fig 4A1, 4B1 and (Farajnia et al., 2014)). Note that 
even in the presence of the KCC2 blocker, a difference in the E/I ratio between photoperiods still 
remains. This is in line with the observation that the percentage of excitatory cells increased to a 
similar degree in slices from mice adapted to long photoperiod and 12:12 condition, suggesting that 
KCC2 activity is important for maintaining E/I balance under all photoperiods. From all neurons that 
were initially inhibitory, about 50% stayed inhibitory, approximately 20-25% turned excitatory, and 
the remaining 25-30% became either non-responsive or responded in a biphasic manner. Moreover, 
about half of the non-responders and a significant part of the biphasic cells turned excitatory (Fig 3A 
and Fig 4A4; Wald chi2(1) = 36.62, p = 1.44 x 10-9+ 4B4; Wald chi2(1) = 5.52, p = 0.019). From all the 
slices measured, regardless of the photoperiod of the animal, the E/I ratio increased after blocking 
KCC2 (SP: Fig 4A2 + 4A3; t(7) = 3.92, p = 0.006, n = 8, and, LP: Fig 4B2 + 4B3; t(7) = 4.40, p = 0.003, n = 
8). Together, these data show that, irrespective of their photoperiod, blocking KCC2 increases the 
amount of GABAergic excitation. 
To determine if the drug influences the baseline [Ca2+]i, we analyzed the baseline [Ca2+]i before and 
after application of either ML077 or DMSO. For all three photoperiods, we found an increase in 
baseline [Ca2+]i after administration of ML077, which was not different to treatment with DMSO (Fig 
S3). Consequently, we can conclude that the rise in baseline [Ca2+]i is not an effect of blocking KCC2 
with ML077.  
Furosemide and bumetanide are two pharmacological blockers that have been widely used to block 
the cotransporters KCC2 and NKCC1. Bumetanide has a higher affinity for NKCC1 than for KCC2 
(Gillen et al., 1996; Payne et al., 2003), but furosemide is known to block both NKCC1 and KCC2 with 
equal potency (Blaesse et al., 2009; Delpire et al., 2009). Moreover, furosemide inhibits N-methyl D-
aspartate (NMDA) and GABAA receptors (Staley, 2002). Blocking NKCC1 with bumetanide, and thus 
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the intrusion of Cl-, does have an effect on the GABAergic response, but not on the polarity of the 
response. Bumetanide lowered the amplitude of GABA-evoked elevations in [Ca2+]i, but could not 
substantially convert GABAergic excitation into inhibition (Choi et al., 2008; Farajnia et al., 2014). A 
recent study by Klett and Allen (2017) demonstrated a larger effect on [Cl-]i in SCN neurons due to 
application of the KCC2 blocker VU0240551 compared to bumetanide, suggesting a significant role of 
KCCs in the regulation of [Cl-]i.  Our results show for the first time that a specific blocker for KCC2, 
ML077 (VU0255011), not only attenuates the GABAergic response in the SCN, but can even cause  a 
reversal of  the polarity of the GABAergic response from inhibition to excitation.  
GABA is a dominant neurotransmitter in the SCN and has important roles in synchronization and 
entrainment (Albus et al., 2005). Modeling approaches and experimental evidence show that GABA 
signaling has significant impact on network function determining basic properties and plasticity of 
the SCN clock (Azzi et al., 2017; DeWoskin et al., 2015). Modulation of SCN network underlies 
encoding seasonal day-length changes with clustering of neuronal activity in short-days and wider 
phase distribution of the pacemaker cells in the SCN during long-days (VanderLeest et al., 2007). 
While there is still some controversy on the potential excitatory action of GABA in the adult SCN (see 
(Albers et al., 2017)), there is mounting evidence for excitatory GABA responses and the role of KCCs  
to regulate Cl- concentration (Choi et al., 2008; Farajnia et al., 2014; Irwin and Allen, 2009; Myung et 
al., 2015). Functionally, the modulation of GABA response types and subsequent changes in E/I 
balance may affect SCN network plasticity. Our data show that just blocking  KKC2 can already 
change the E/I balance in the SCN from a short-day to a long-day phenotype. Whether the changes in 
GABAergic E/I balance are sufficient or necessary for photoperiodic encoding by the SCN still needs 
to be established. 
An imbalance between GABAergic excitation and inhibition is implicated in several neurological 
disorders (Marín, 2012; Sgadò et al., 2011) and because of its ability to reduce the level of GABAergic 
excitation, bumetanide is already used in several clinical trials for epilepsy and autism (Bruining et al., 
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2015; Du et al., 2015; Eftekhari et al., 2013; Lemonnier et al., 2012; Pressler et al., 2015). Still, there is 
a demand for improved pharmacological blockers for the cotransporters, since the kinetics of 
bumetanide and furosemide are not optimal due to short half-life time and bad passage of the blood-
brain barrier (Brandt et al., 2010). Our results already show the high effectiveness of ML077 for 
manipulating E/I balance in neuronal networks and this drug has been further optimized as  
VU0463271 (Delpire et al., 2012). Studies have shown that this new inhibitor leads to hippocampal 
hyperexcitability and seizure activity both in slices and in vivo (Kelley et al., 2016; Sivakumaran et al., 
2015). These new and optimized KCC2 blockers are important tools for fundamental research on the 
role of chloride homeostasis in regulating E/I balance in neuronal networks.   
While the mechanisms regulating and maintaining [Cl-]i are still under debate, previous studies have 
shown a prominent role for CCCs (for review: (Ben-Ari, 2002; Payne et al., 2003)). Reduction or 
absence of KCC2 or its functionality leads to decreased inhibitory GABAergic actions (Deeb et al., 
2011; Doyon et al., 2015; Hubner et al., 2001; Rivera et al., 1999; Zhu et al., 2005). Moreover, 
chloride dysregulation caused by reduced KCC2 expression or function is associated with numerous 
neurological disorders including epilepsy, chronic pain, and schizophrenia (Ben-Ari et al., 2012; Kelley 
et al., 2016; Miles et al., 2012; Price et al., 2005). Recently, Glykys et al. questioned the prominent 
role of KCC2 and NKCC1 by showing that blocking these cotransporters with VU0240551 and 
bumetanide did not change [Cl-]i , but that local intracellular and extracellular concentrations of 
anions determined [Cl-]i (Glykys et al., 2014a). Since the argument on the role of immobile anions in 
[Cl-]i regulation is not fully resolved yet (Glykys et al., 2014b; Luhmann et al., 2014; Voipio et al., 
2014), this alternative or additional mechanism deserves further study. With our data, we show a 
significant increase in GABAergic excitation after blocking KCC2 with the new antagonist ML077. This 
GABA-mediated neuronal excitation presumably results from an increased [Cl-]i  and a correlated 
shift in GABA reversal potential. While impermeable anions may still contribute to the maintenance 
of [Cl-]i, our results support the hypothesis that cation-chloride-cotransporters play an important role 
in regulating the chloride homeostasis . 
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The question remains how photoperiod can affect chloride cotransporters to induce a change in E/I 
balance. Myung et al. recently demonstrated an increase in [Cl-]i in the SCN cells after entrainment to 
long photoperiod. Moreover, application of furosemide to long photoperiod entrained SCN slices 
increased synchronization and lengthened the period of the circadian rhythms in Bmal1-Eluc in 12:12 
entrained SCN explants to levels shown for the short photoperiod entrained SCN (Myung et al., 
2015). Combined, these results suggest that modulation of the chloride levels in the cells can play a 
role in day-length encoding in the SCN. At the transcript level, the expression of both KCC2 and 
NKCC1 were upregulated in long photoperiod, when compared to short photoperiod, and the relative 
expression ratio between NKCC1 and KCC2 was significantly higher under long photoperiod in the 
dorsal SCN (Myung et al., 2015). Because these results only show the increase at mRNA level, one 
cannot conclude that NKCC1 causes the higher [Cl-]i  under long photoperiod. More important than 
mRNA or even protein expression is the functional expression and/or regulation of KCC2 vs NKCC1. 
The functionality of KCC2 is modulated by both transcriptional and post-transcriptional routes. 
(De)phosphorylation, recycling, and intracellular trafficking are, amongst others, examples of how 
KCC2 can be modulated and its function can be influenced (Kahle et al., 2013; Kahle and Delpire, 
2016; Kaila et al., 2014; Lee et al., 2011; Mahadevan and Woodin, 2016). Therefore, the decrease in 
functional KCC2 and/or increase in functional NKCC1 in long photoperiod may contribute to elevated 
[Cl-]i and consequently to the rise in GABAergic excitation. From our data we conclude that KCC2 
plays an important role in the hyperpolarizing effect of GABA and thus in maintaining a low [Cl-]i. 
These data have potential societal impact as use of artificial light in modern society leads to “longer 
day length”. Moreover, GABAergic function is essential for sleep, anxiety, and depression. Whether 
day length also affects GABAergic function in other brain areas through this mechanism remains to 
be investigated.  
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Fig. 1 SCN neurons can change GABAergic response after blocking KCC2 with ML077 
(A) Examples of Fura-2-AM loaded SCN neurons from mice entrained to LD12:12. Color 
scale indicates fluorescence intensity at 380 nm excitation in arbitrary units. (Scale bar, 10 
µm) (B) On top, a sketch of the experimental protocol is depicted. SCN slices were 
continuously superfused with ACSF and Ca2+ transients were recorded  in response to focal 
applications of GABA (200 µM) given before and after a 10-minute incubation with ML077. 
Below example traces of Ca2+ transients of 4 neurons are shown demonstrating the changes in 
GABAergic response after blocking KCC2 with ML077. (Scale bars, 50 nM, 30 s)  
Fig. 2 Blocking KCC2 with ML077 caused an increase in GABA-mediated excitation in 
SCN neurons of mice entrained to LD12:12. (A) Pie charts depicting the distributions of 
response types of the same SCN neurons on GABAergic stimulation before and after 
incubation with ML077 (number of cells: n = 499; measured in 23 slices of 8 animals). (B) 
Ratios of excitatory to inhibitory GABAergic signaling before and after incubation with 
ML077. Each value indicates the ratio of all the cells measured from one animal. (C) Increase 
in E/I ratio for each experiment after incubation with ML077 (B + C: (paired t-test; p = 
0.011). 
Fig. 3 GABAergic response type in SCN neurons (LD 12:12) changes after blocking 
KCC2 with ML077. (A) Distribution of GABAergic response types after incubation with 
ML077 grouped per initial GABAergic response type (number of cells per initial response 
type shown on the x-axis). The fraction of cells for each response type resulting from the 
ML077 treatment is depicted on the y-axis and shows a significant effect of the drug on 
response type distribution (total number of cells: n = 499; measured in 23 slices of 8 animals, 
Wald Chi square test; p = 1 x 10-6). (B) Distribution of GABAergic response types after 
incubation with control solution (4 ppm DMSO in ACSF) grouped per initial GABAergic 
response type (number of cells per initial response type shown on the x-axis). The fraction of 
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cells for each response type resulting from the DMSO treatment is depicted on the y-axis and 
shows no significant effect of the solvent (total number of cells: n = 248, measured in 11 
slices of 4 animals, Wald Chi square test; p = 0.24). 
Fig. 4 Changes in response type in SCN neurons after blocking KCC2 with ML077 is 
similar for all photoperiods. (A) Pie charts depicting the distributions of response types on 
GABAergic stimulation before and after incubation with ML077 (number of cells: n = 387; 
measured in 19 slices of 8 SCN) for SP entrained neurons. (B) Ratios of excitatory to 
inhibitory GABAergic signaling before and after incubation with ML077 for SP entrained 
neurons. Each value indicates the ratio of all the cells measured from one animal. (C) Increase 
in E/I ratio for each experiment after incubation with ML077 (B + C: (paired t-test; p = 
0.006)). (D) Distribution of GABAergic response types after incubation with ML077 grouped 
per initial GABAergic response in SCN cells of mice entrained to SP (number of cells per 
initial response type shown on the x-axis). The fraction of cells for each response type 
resulting from the ML077 treatment is depicted on the y-axis and shows a significant effect of 
the drug on response type distribution (Wald Chi square test; p = 1.44 x 10-9). (E) Pie charts 
depicting the distributions of response types on GABAergic stimulation before and after 
incubation with ML077 (number of cells: n = 557; measured from 24 slices of 8 SCN) for LP 
entrained neurons. (F) Ratios of excitatory to inhibitory GABAergic signaling before and after 
incubation with ML077 for LP entrained neurons. Each value indicates the ratio of all the 
cells measured from one animal. (G) Increase in E/I ratio for each experiment after incubation 
with ML077 (F + G: (paired t-test; p = 0.003). (H) Distribution of GABAergic response types 
after incubation with ML077 grouped per initial GABAergic response in SCN cells of mice 
entrained to LP (number of cells per initial response type shown on the x-axis). The fraction 
of cells for each response type resulting from the ML077 treatment is depicted on the y-axis 
16 
 
and shows a significant effect of the drug on response type distribution (Wald Chi square test; 
p =0.019).  
Fig S1 Changes in response type in SCN neurons after blocking KCC2 with ML077. 
Number of cells that change response type after incubation with ML077 grouped per initial 
GABAergic response in SCN cells of mice entrained to (A) LD12:12, (B) SP, and (C) LP. 
The number of cells for each response type resulting from the ML077 treatment is depicted on 
the y-axis and shows a significant effect of the drug on response type distribution (number of 
cells per initial response type shown on the x-axis) (LD12:12: Wald Chi square test; p = 1 x 
10-6 SP: Wald Chi square test; p = 1.44 x 10-9 LP: Wald Chi square test; p =0.019).  
Fig S2 DMSO treatment does not affect GABAergic responses. On top, a sketch of the 
experimental protocol is depicted. SCN slices were continuously superfused with ACSF and 
Ca2+ transients were recorded  in response to focal applications of GABA (200 µM) given 
before and after a 10-minute incubation with DMSO in ACSF (4ppm). Below example traces 
of Ca2+ transients of 5 neurons are shown demonstrating the GABAergic responses before and 
after incubation with control solution (4 ppm DMSO in ACSF). (Scale bars, 50 nM, 30 s) 
Fig. S3 Rise in baseline [Ca2+]i is not an effect of blocking KCC2 with ML077. Bar graphs 
show average increase (means ± SEM) in baseline [Ca2+]i after application of ML077 and 
DMSO from all cells of animals entrained to LD12:12 (Mann-Whitney test: p = 0.069, 
ML077: n = 499, DMSO: n = 269), SP (Mann-Whitney test: p = 0.0141, ML077: n = 387, 
DMSO: n = 149), and LP (Mann-Whitney test: p = 0.153, ML077: n = 557, DMSO: n = 319).  
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